LAUSR

Simple Summary Contagious agalactia (CA), caused by Mycoplasma agalactiae (M. agalactiae), is a very important disease in dairy sheep. It is distributed worldwide, and causes a marked drop or even complete loss of milk production, arthritis, keratoconjunctivitis, pneumonia, and septicemia. The current study represents the first investigation evaluating the synergistic effect of combining Staphylococcus aureus (S. aureus) within the M. agalactiae vaccine. Apart from the previously known benefits of combined vaccines, such as reduced production costs, time and effort saving, simplifying the immunization schedule, and minimizing the stress of multiple vaccinations, the current study recorded for the first time that the involvement of S. aureus in inactivated vaccines against M. agalactiae elicited a higher antibody response against M. agalactiae, detected by ELISA, than the monovalent M. agalactiae vaccine. The humoral immune response and hematological parameters were significantly improved and manifested by the increased antibody titre, total leukocytic count, neutrophils, and blood platelets. Moreover, the local glandular immunity of the udder, assessed by the somatic cell count (SCC), was enhanced. Abstract In Italy, dairy sheep farming represents a vital agro-industry sector, but it is still challenged by contagious agalactia (CA), which is endemic there, and vaccination is the most economical and sustainable tool for control. This study aimed to evaluate the combined Mycoplasma agalactiae (Ma)-Staphylococcus aureus (Sa) vaccine (Ma–Sa) against the Ma monovalent vaccine in ewes. Twelve primiparous Ma-free ewes were randomly grouped into three equal groups: first, the control group injected with placebo, second, the group vaccinated with the Ma monovalent vaccine, and third, the group vaccinated with Ma–Sa combined vaccine, with two S/C doses at 45-day intervals. The animals were examined for serological, hematological, and somatic cell count (SCC) changes for 17 successive weeks. A significant increase in anti-Ma antibody mean titers, leukocytes, and platelets was observed in the vaccinated animals, with the highest values in those who received the combined vaccine. Neutrophils were high only in the animals who received the combined vaccine. SCC was lower in the vaccinated animals during the first six weeks. This study concludes that the combined Ma–Sa vaccines enhance immune response and potentiate its efficacy against Ma. This improvement might be attributed to the sensitization/activation effect of S. aureus on platelets, which are recoded to act as a key regulator for the coordination of all components of the innate immune system. Even though this study included a small number of animals, its findings about the potentialities of this inactivated vaccine in the control of CA are strongly encouraging. Further confirmation might be needed through additional replicates and a challenge study is needed before proceeding with widespread use.